From hepatic steatosis in obesity to cirrhosis, in the absence of alcoholic intoxication;De la stéatose hépatique de l'obèse à la cirrhose, en l'absence d'intoxication alcoolique

Presse Medicale

Volumn 32, Issue 11, 2003, Pages 512-518

  Larrey, Dominique ^a  

^a HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMIODARONE; ANTIOXIDANT; ASPARAGINASE; BEZAFIBRATE; CHLOROQUINE; CORTICOSTEROID; DILTIAZEM; GEMFIBROZIL; HYCANTHONE; METHOTREXATE; NIFEDIPINE; PERHEXILINE; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; URSODEOXYCHOLIC ACID;

ALCOHOL INTOXICATION; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FATTY LIVER; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; METABOLIC DISORDER; OBESITY; PREVALENCE; PROGNOSIS; REVIEW; RISK FACTOR; TREATMENT PLANNING; VALIDATION PROCESS;

DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FATTY LIVER; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER FUNCTION TESTS; OBESITY; RISK FACTORS;

EID: 0037460812     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. e Ed. Médecine-Sciences Flammarion 2000; 64-67
2. nd edn, vol II, Oxford University Press 1999; 1252-1256
3. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo Clin Proc 1980; 55: 434-8
4. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999; 353: 1634-6
5. Diehl AM. Nonalcoholic steatohepatitis. Sem Liv Dis 1999; 19: 221-9
6. Petit P, Zarski J. P. Les stéato-hépatites non alcooliques. Gastroenterol Clin Biol 2000; 2: 157-9
7. Oppert JM, Rolland-Cachera MF. Prévalence, évolution dans le temps et conséquences économiques de l'obésité. Medecine/Sciences 1998; 14: 939-43
8. Basdevant A, Laville M, Ziegler O. Guide pratique pour le diagnostic, la prevention, le traitement des obésités en France. Diabetes Metab 1988; 24 (suppl.2): 10-42
9. Charles MA. Actualités épidémiologiques de l'obésté et du diabéte de type 2 en France. Diabetes & Metabolism 2000; 26: 17-20
10. Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Sem Liv Dis 2001; 21: 71-80
11. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Sem Liv Dis 2001; 21: 3-16
12. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Sem Liv Dis 2001; 21: 17-26
13. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Sem Liv Dis 2001; 21: 27-41
14. Larrey D. Pathologies hépatiques mitochondriales. Gastroenterol Clin Biol 2001; 25: B117-22
15. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Sem Liv Dis 2001; 21: 57-69
16. Angulo P, Keach JC, Kennetti PB, Lindo KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.
17. Ratziu V, Giral P, Charlotte F et al. Liver, fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123.
18. Poonawala A, Nair SP, Thuluwath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32: 689-92.
19. Bonkovsky HL, Jawaid Q, Tortorelli K et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 421-9
20. George DK, Goldwurm, McDonald GA et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-18.
21. Moirand R, Mortaji AM, Loreal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997; 349: 95-7.
22. Angulo P, Lindor KD. Insulin resistance and mitochonfrial abnormalities in NASH: a cool look into a burning issue. Gastroenterology 2001; 120: 1281-5
23. Sanyal AJ, Campbell-Sargent C, Mirshhi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92
24. Younossi ZM, Gramlich T, Bacon BR et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999; 30: 847-50.
25. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholi fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
26. Garcia-Monzon C, Martin-Perez E, Lo Iacono O et al. Characterization of pathogenic and pronostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000; 33: 716-24
27. Niemela O, Parkkila S, Juvonen RO, Viitala K, Gelboin HV, Pasanen M. Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. J Hepatol 2000; 33: 893-901.
28. Ledercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP 2E1 and CYP 4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-75.
29. Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 2000; 26: 98-106
30. Farrell GC. Is bacterial ash the flash that ignites NASH? Gut 2001; 48: 148-53.
31. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 20: 1467-76.
32. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Sem Liv Dis 2001; 21: 81-8
33. Epeirier JM, Blanc P, D'Abrigeon G et al. Cirrhose grave et transplantation hepatique: complication inédite des régimes amaigrissants. Gastro-entérologie Oinique et Biologique 1995; 19: 737
34. Capron JP, Delamarre J, Dupas JL, Braillon A, Degott C, Quenum C. Fasting in obesity. Another cause of liver injury with alcoholic hyaline? Dig Dis Sci 1982; 265-8
35. Barbare J.-C. Les NASH: saigner ou laisser fer. Gastroenterologie 2000; 7: 204-7